References
- Munoz N, Bosch FX, de Sanjose S, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group, et al. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–527.
- Shah KV, Howley, PM. Field virology: papillomaviruses. Fields BN, Knipe DM, Howley PM, editors. New York: Raven Press; 1996. p. 2078–2109.
- Brendle SA, Culp TD, Broutian TR, et al. Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58. J Gen Virol. 2010;91(Pt 7):1834–1839.
- WHO. 2022. Human papillomavirus (HPV) and cervical cancer. https://www.who.int/en/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer.
- Kabir A, Bukar M, Nggada HA, et al. Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria. Pan Afr Med J. 2019;33:284.
- Baker TS, Newcomb WW, Olson NH, et al. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J. 1991;60(6):1445–1456.
- Yaegashi N, Jenison SA, Valentine JM, et al. Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions. J Virol. 1991;65(3):1578–1583.
- Wang JW, Roden RBS. L2, the minor capsid protein of papillomavirus. Virology. 2013;445(1–2):175–186.
- Tan L, Zhang TY. Cellular receptor binding and entry of human papillomavirus. Virol J. 2010;7(1):1–7.
- Brown MJ, Seitz H, Towne V, et al. Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58. Clin Vaccine Immunol. 2014;21(4):587–593.
- Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol. 2005;12(8):959–969.
- Pastrana DV, Buck CB, Pang YYS, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology. 2004;321(2):205–216.
- Zhang Y, He Y, Li L, et al. Development and characterization of an HPV18 test kit using two novel HPV18 type-specific monoclonal antibodies. Diagn Pathol. 2018;13(1):55.
- Sehr P, Rubio I, Seitz H, et al. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One. 2013;8(10):e75677.
- Orlandi R, Güssow DH, Jones PT, et al. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989;86(10):3833–3837.
- Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285–4289.
- Liu YY, Zhang Y, Zhang GF, et al. Development of HPV58 type-specific antibodies and detection kit. Prep Biochem Biotechnol. 2023;53(2):223–229.
- Liu YY, Zhang Y, Zhang GF, et al. Development and characterization of anti‐HPV16 monoclonal antibodies for assembly of an HPV16 detection kit. Biotechnol Appl Biochem. 2022. DOI: 10.1002/bab.2384.